SCHEMBL3512224

SCHEMBL3512224

COc1ccc(N(C(=O)O)C(C)(C)C)cc1Oc1ccc2nc(NC(=O)C3CC3)sc2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.51
ALDH1A1 P00352 2/20 0.45
MAPT P10636 1/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KDR P35968 5/20 0.45
PDGFRB P09619 2/20 0.45
KIT P10721 2/20 0.45
FLT1 P17948 1/20 0.45
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
HSP90AA1 P07900 1/20 0.42
MAP4K1 Q92918 1/20 0.41
NPSR1 Q6W5P4 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
IKBKB O14920 1/20 0.39
RAF1 P04049 1/20 0.39
ERBB2 P04626 1/20 0.39
CDK1 P06493 1/20 0.39
SRC P12931 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1258993 0.90 BRAF (0.57) BRAFALDH1A1MAPTTSHRHSD17B10
SCHEMBL3510563 0.84 BRAF (0.58) BRAFKDRPDGFRBKITFLT1
SCHEMBL2853876 0.84 NPC1 (0.51) BRAFALDH1A1MAPTTSHRHSD17B10
SCHEMBL2859325 0.83 KDR (0.53) BRAFALDH1A1MAPTTSHRHSD17B10
SCHEMBL2857653 0.83 BRAF (0.51) BRAFALDH1A1MAPTTSHRHSD17B10
SCHEMBL2856533 0.82 NPC1 (0.61) BRAFALDH1A1MAPTTSHRHSD17B10
SCHEMBL3510114 0.80 BRAF (0.54) BRAFKDRPDGFRBKITFLT1
SCHEMBL2452684 0.79 BRAF (0.67) BRAFKDRPDGFRBKITFLT1
SCHEMBL3512217 0.79 BRAF (0.46) BRAFKDRNPC1RAB9A
SCHEMBL2456610 0.76 KDR (0.48) BRAFKDRPDGFRBKITFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 BRAF 1/4885ALDH1A1 625/4885MAPT 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.